Hulubă Iulia-Patricea, Crecan-Suciu Bianca Daniela, Păunescu Ramona, Micluția Ioana Valentina
Department of Neurosciences, 'Iuliu Hațieganu' University of Medicine and Pharmacy, Cluj-Napoca 400012, România.
Psychiatric Clinic, Emergency County Hospital, Cluj-Napoca 400012, România.
Biomed Rep. 2025 Feb 20;22(4):71. doi: 10.3892/br.2025.1949. eCollection 2025 Apr.
Major depressive disorder represents one of the most common psychiatric diagnosis, and was ranked by World Health Organization as the third cause of morbidity and mortality worldwide, expecting to become the first cause by 2030. The prevalence of depression is higher in women than in men, once the puberty sets. This may be explained by the hormonal fluctuations, estrogen and progesterone, over a woman's lifespan. Some of the women may experience severe mood symptoms during the luteal phase of the menstrual cycles, known as premenstrual dysphoric disorder. In addition, it has been shown that the use of hormonal contraceptives, especially oral contraceptives (OC), may determine an induced depressive disorder. The risk of induced depressive disorder is even higher in women who start an OC treatment during adolescence, mainly because this is the period when the hormonal milieu is developing. Another important period of hormonal fluctuations is after delivery. It is described such as a hormonal 'withdrawal state' because in a matter of days postpartum, the hormonal levels decrease down to the levels of a non-pregnant woman. It is worth to mention that this extreme decreasing of estrogen and progesterone is not enough in order to develop postpartum depression. It has been suggested that postpartum depression may be a consequence to differential activation of estrogen genes. Fortunately, since 2019, Food and Drug Administration approved the first specific hormonal treatment for postpartum depression, represented by brexanolone. The last period of hormonal changes is the transition to menopause, in which depressive symptoms may be determined by day-to-day hormonal fluctuations. There is a lot more to explore in this field for future research, regarding if there really is a direct link between the levels of estrogen and progesterone and depressive disorder, and also regarding different hormonal therapies.
重度抑郁症是最常见的精神疾病诊断之一,世界卫生组织将其列为全球发病和死亡的第三大原因,预计到2030年将成为首要原因。青春期开始后,女性抑郁症的患病率高于男性。这可能是由于女性一生中雌激素和孕激素的激素波动所致。一些女性在月经周期的黄体期可能会出现严重的情绪症状,即经前烦躁障碍。此外,研究表明,使用激素避孕药,尤其是口服避孕药(OC),可能会引发抑郁症。在青春期开始服用OC治疗的女性中,引发抑郁症的风险更高,主要是因为这个时期激素环境正在发育。另一个重要的激素波动期是产后。这被描述为一种激素“戒断状态”,因为在产后几天内,激素水平会降至未怀孕女性的水平。值得一提的是,雌激素和孕激素的这种急剧下降并不足以导致产后抑郁症。有人认为,产后抑郁症可能是雌激素基因差异激活的结果。幸运的是,自2019年以来,美国食品药品监督管理局批准了首个针对产后抑郁症的特异性激素治疗药物——布雷沙诺龙。激素变化的最后一个时期是向更年期的过渡,在此期间,日常激素波动可能会导致抑郁症状。关于雌激素和孕激素水平与抑郁症之间是否真的存在直接联系,以及不同的激素疗法,该领域还有很多有待未来研究探索的地方。